Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPLETION OF ENROLLMENT POSITIONS CELZ FOR NEAR-TERM DATA CATALYSTS AND ACCELERATES PATH TOWARD COMMERCIALIZATION OF A TRANSFORMATIVE, NON-OPIOID THERAPY FOR CHRONIC LOWER BACK PAIN COMPLETION OF ENROLLMENT POSITIONS CELZ FOR NEAR-TERM DATA CATALYSTS AND ACCELERATES PATH TOWARD COMMERCIALIZATION OF A TRANSFORMATIVE, NON-OPIOID THERAPY FOR CHRONIC LOWER BACK PAIN

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. COMPLETES ENROLLMENT IN FDA-CLEARED ADAPT TRIAL FOR CELZ-201-OLASTROCEL, MARKING MAJOR CLINICAL INFLECTION POINT

GLOBAL ASSIGNMENT OF THIS UNIQUE NAME ENHANCES INTERNATIONAL CLARITY, STRENGTHENS REGULATORY POSITIONING, AND SUPPORTS OLASTROCEL'S ADVANCEMENT ACROSS LARGE UNMET-NEED GLOBAL MARKETS GLOBAL ASSIGNMENT OF THIS UNIQUE NAME ENHANCES INTERNATIONAL CLARITY, STRENGTHENS REGULATORY POSITIONING, AND SUPPORTS OLASTROCEL'S ADVANCEMENT ACROSS LARGE UNMET-NEED GLOBAL MARKETS

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES WORLD HEALTH ORGANIZATION APPROVAL OF OLASTROCEL AS INN FOR LEAD ALLOGENEIC CELL THERAPY CELZ-201

SELECTS GREENSTONE BIOSCIENCES TO ACCELERATE AI-DRIVEN IPSC PRECISION MEDICINE PLATFORM SELECTS GREENSTONE BIOSCIENCES TO ACCELERATE AI-DRIVEN IPSC PRECISION MEDICINE PLATFORM

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. IGNITES NEXT-GEN REGENERATIVE BIODEFENSE INITIATIVE FOR U.S. VETERANS EXPOSED TO BURN PITS

PHOENIX, OCT. 29, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., (NASDAQ: CELZ) (THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING REGENERATIVE IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AGREEMENTS WITH CERTAIN HOLDERS OF ITS EXISTING WARRANTS FOR THE IMMEDIATE EXERCISE OF OUTSTANDING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 1,116,136 SHARES OF COMMON STOCK OF THE COMPANY ORIGINALLY ISSUED IN MARCH 2025, AT THEIR CURRENT EXERCISE PRICE OF $3.75 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT ON FORM S-3 (FILE NO.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES AGREEMENTS FOR EXERCISE OF WARRANTS FOR $4.2 MILLION GROSS PROCEEDS

ONGOING PHASE II CLINICAL TRIALS, RECENTLY ISSUED PATENTS, AND AI INTEGRATION INITIATIVESSET THE STAGE FOR CONTINUING PROGRESS IN 2026 ONGOING PHASE II CLINICAL TRIALS, RECENTLY ISSUED PATENTS, AND AI INTEGRATION INITIATIVESSET THE STAGE FOR CONTINUING PROGRESS IN 2026

Creative Medical Technology Holdings, Inc.

CELZ

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Creative Medical Technology Holdings, Inc.

CELZ.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CELZ